Low LDL-C: Is It all Good News?

2024-9-10

Should We Use Aspirin or P2Y12 Inhibitor Monotherapy in Stable Ischemic Heart Disease?

2024-9-7

Health Data Sciences and Cardiovascular Disease in Africa: Needs and the Way Forward

2024-9-6

Health Data Sciences and Cardiovascular Diseases in South Asia: Innovations and Challenges in Digital Health

2024-9-6

Is Family History for the Management of Cardiovascular Health in Youth Still Relevant in Clinical Practice?

2024-8-27

Obicetrapib—the Rebirth of CETP Inhibitors?

2024-8-16

PCSK9 and Coronary Artery Plaque—New Opportunity or Red Herring?

2024-8-16

Targeting Macrophage Phenotypes and Metabolism as Novel Therapeutic Approaches in Atherosclerosis and Related Cardiovascular Diseases

2024-8-12

Therapeutic Monoclonal Antibodies for Metabolic Disorders: Major Advancements and Future Perspectives

2024-7-15

The Role of Social Determinants of Health in Atherosclerotic Cardiovascular Disease

2024-7-9

Social Phenotyping for Cardiovascular Risk Stratification in Electronic Health Registries

2024-7-8

When Does Primary Prevention Encroach on Secondary Prevention?

2024-7-8

Cardiovascular Risk Estimation and Stratification Among Individuals with Hypercholesterolemia

2024-7-5

A Potential Role for MAGI-1 in the Bi-Directional Relationship Between Major Depressive Disorder and Cardiovascular Disease

2024-7-3

Cholesterol Lowering in Older Adults: Should We Wait for Further Evidence?

2024-7-3

The Emerging Specialty of Cardio-Rheumatology

2024-6-24

The Role of Reverse Cascade Screening in Children with Familial Hypercholesterolemia: A Literature Review and Analysis

2024-6-18

Lipoprotein (a)-Related Inflammatory Imbalance: A Novel Horizon for the Development of Atherosclerosis

2024-6-15

Unraveling the miRNA Puzzle in Atherosclerosis: Revolutionizing Diagnosis, Prognosis, and Therapeutic Approaches

2024-6-13

Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American College of Cardiology Conference

2024-6-3

Myocardial Bridge and Atherosclerosis, an Intimal Relationship

2024-6-1

Hypercholesterolemia and the Increased Risk of Vascular Dementia: a Cholesterol Perspective

2024-5-30

Stress, Vascular Smooth Muscle Cell Phenotype and Atherosclerosis: Novel Insight into Smooth Muscle Cell Phenotypic Transition in Atherosclerosis

2024-5-30

GLP-1 Receptor Agonists and Cardiovascular Disease: What Do Clinicians Need to Know?

2024-5-29

The Role of Bacterial Extracellular Membrane Nanovesicles in Atherosclerosis: Unraveling a Potential Trigger

2024-5-28

The Role of Sleep in Cardiovascular Disease

2024-5-25

Artificial Intelligence in Cardiovascular Disease Prevention: Is it Ready for Prime Time?

2024-5-23

From Atherosclerosis to Spontaneous Coronary Artery Dissection: Defining a Clinical and Genetic Risk Spectrum for Myocardial Infarction

2024-5-18

Comparative Analysis of Atherogenic Lipoproteins L5 and Lp(a) in Atherosclerotic Cardiovascular Disease

2024-5-16

Noninvasive Atherosclerotic Phenotyping: The Next Frontier into Understanding the Pathobiology of Coronary Artery Disease

2024-5-10

Pharmacotherapy for Coronary Artery Disease and Acute Coronary Syndrome in the Aging Population

2024-5-9

Roles and Mechanisms of miRNAs in Abdominal Aortic Aneurysm: Signaling Pathways and Clinical Insights

2024-5-6

The Effects of FABP4 on Cardiovascular Disease in the Aging Population

2024-5-1

Cardiovascular Health and Disease in the Pakistani American Population

2024-4-26

Subclinical Atherosclerosis to Guide Treatment in Dyslipidemia and Diabetes Mellitus

2024-4-25

What Causes Premature Coronary Artery Disease?

2024-4-4

Cardiovascular Effects of Stimulators of Soluble Guanylate Cyclase Administration: A Meta-analysis of Randomized Controlled Trials

2024-4-2

Oral PCSK9 Inhibitors

2024-3-27

Gene Editing for the Treatment of Hypercholesterolemia

2024-3-18

The Role of Genetics in Advancing Cardiometabolic Drug Development

2024-3-7

Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 American Heart Association Scientific Sessions

2024-3-5

European Lipid Guidelines and Cardiovascular Risk Estimation: Current Status and Future Challenges

2024-3-2

Implications of Bias in Artificial Intelligence: Considerations for Cardiovascular Imaging

2024-2-16

Novel Therapies for Lipoprotein(a): Update in Cardiovascular Risk Estimation and Treatment

2024-2-5

How Will Our Practice Change After the CLEAR Outcomes Trial?

2024-1-31

Increased Cardiovascular Risk in Young Patients with CKD and the Role of Lipid-Lowering Therapy

2024-1-30

Lipoprotein(a): from Causality to Treatment

2024-1-22

Correction to: Whether and Why Do We Need a Vaccine Against Atherosclerosis? Can We Expect It Anytime Soon?

2024-1-22

Psychological Health and Ischemic Heart Disease in Women: A Review of Current Evidence and Clinical Considerations across the Healthspan

2024-1-19

Targeting the Gut Microbiome to Treat Cardiometabolic Disease

2024-1-5